CAR-T Therapy Shows Durable Benefits in Myasthenia Gravis
(MedPage Today) -- Mivocabtagene autoleucel (miv-cel), an autologous CD19 chimeric antigen receptor (CAR)-T cell therapy, showed benefits lasting 6 months or longer for generalized myasthenia gravis patients in the phase II portion of the KYSA...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.